{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T16:42:59Z","timestamp":1786552979909,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["12231018"],"award-info":[{"award-number":["12231018"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Interdiscip Sci Comput Life Sci"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12539-025-00779-3","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:33:50Z","timestamp":1761028430000},"page":"838-848","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Hypergraph-Based Model for Predicting Potential Drug Combinations in Cancer Therapy"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1402-7485","authenticated-orcid":false,"given":"Qi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiying","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"779_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-018-0141-x","volume":"17","author":"M Tyers","year":"2019","unstructured":"Tyers M, Wright GD (2019) Drug combinations: a strategy to extend the life of antibiotics in the 21st century. Nat Rev Microbiol 17:141\u2013155. https:\/\/doi.org\/10.1038\/s41579-018-0141-x","journal-title":"Nat Rev Microbiol"},{"key":"779_CR2","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41586-022-04437-2","volume":"603","author":"P Jaaks","year":"2022","unstructured":"Jaaks P, Coker EA, Vis DJ et al (2022) Effective drug combinations in breast, colon, and pancreatic cancer cells. Nature 603:166\u2013173. https:\/\/doi.org\/10.1038\/s41586-022-04437-2","journal-title":"Nature"},{"key":"779_CR3","doi-asserted-by":"publisher","unstructured":"Chen X, Huang L (2023) Computational model for drug research. Brief Bioinform 24:bbac615. https:\/\/doi.org\/10.1093\/bib\/bbac615","DOI":"10.1093\/bib\/bbac615"},{"key":"779_CR4","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1126\/science.aay3041","volume":"367","author":"J Liu","year":"2020","unstructured":"Liu J, Gefen O, Ronin I et al (2020) Effect of tolerance on the evolution of antibiotic resistance under drug combinations. Science 367:200\u2013204. https:\/\/doi.org\/10.1126\/science.aay3041","journal-title":"Science"},{"key":"779_CR5","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/s41467-019-09186-x","volume":"10","author":"F Cheng","year":"2019","unstructured":"Cheng F, Kov\u00e1cs IA, Barab\u00e1si AL (2019) Network-based prediction of drug combinations. Nat Commun 10:1197. https:\/\/doi.org\/10.1038\/s41467-019-09186-x","journal-title":"Nat Commun"},{"key":"779_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.artmed.2017.05.008","volume":"83","author":"X Li","year":"2017","unstructured":"Li X, Xu Y, Cui H et al (2017) Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles. Artif Intell Med 83:35\u201343. https:\/\/doi.org\/10.1016\/j.artmed.2017.05.008","journal-title":"Artif Intell Med"},{"key":"779_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jtbi.2017.01.019","volume":"417","author":"Q Xu","year":"2017","unstructured":"Xu Q, Xiong Y, Dai H et al (2017) PDC-SGB: prediction of effective drug combinations using a stochastic gradient boosting algorithm. J Theor Biol 417:1\u20137. https:\/\/doi.org\/10.1016\/j.jtbi.2017.01.019","journal-title":"J Theor Biol"},{"key":"779_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1504\/IJCBDD.2020.105093","volume":"13","author":"WH Chiang","year":"2020","unstructured":"Chiang WH, Shen L, Li L et al (2020) Drug-drug interaction prediction based on co-medication patterns and graph matching. Int J Comput Biol Drug Des 13:36\u201357. https:\/\/doi.org\/10.1504\/IJCBDD.2020.105093","journal-title":"Int J Comput Biol Drug Des"},{"issue":"1","key":"779_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.synbio.2024.09.003","volume":"10","author":"Q Wang","year":"2024","unstructured":"Wang Q, Liu X, Yan G (2024) Predicting effective drug combinations for cancer treatment using a graph-based approach. Synth Syst Biotechnol 10(1):148\u2013155. https:\/\/doi.org\/10.1016\/j.synbio.2024.09.003","journal-title":"Synth Syst Biotechnol"},{"key":"779_CR10","unstructured":"Wu B, Wang Q (2025) DiffGraphTrans: a differential attention-based approach for extracting meaningful features of drug combinations. In: Learning Meaningful Representations of Life (LMRL) Workshop at ICLR 2025. https:\/\/openreview.net\/forum?id=llfM9B2QML"},{"key":"779_CR11","doi-asserted-by":"publisher","first-page":"4782","DOI":"10.1093\/bioinformatics\/btac579","volume":"38","author":"X Liu","year":"2022","unstructured":"Liu X, Song C, Liu S et al (2022) Multi-way relation-enhanced hypergraph representation learning for anti-cancer drug synergy prediction. Bioinformatics 38:4782\u20134789. https:\/\/doi.org\/10.1093\/bioinformatics\/btac579","journal-title":"Bioinformatics"},{"key":"779_CR12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41597-022-01360-z","volume":"9","author":"G Shtar","year":"2022","unstructured":"Shtar G, Azulay L, Nizri O et al (2022) CDCDB: a large and continuously updated drug combination database. Sci Data 9:263. https:\/\/doi.org\/10.1038\/s41597-022-01360-z","journal-title":"Sci Data"},{"key":"779_CR13","doi-asserted-by":"publisher","first-page":"D1372","DOI":"10.1093\/nar\/gkae791","volume":"53","author":"F Li","year":"2025","unstructured":"Li F, Mou M, Li X et al (2025) DrugMAP 2.0: molecular atlas and pharma-information of all drugs. Nucleic Acids Res 53:D1372\u2013D1382. https:\/\/doi.org\/10.1093\/nar\/gkae791","journal-title":"Nucleic Acids Res"},{"key":"779_CR14","unstructured":"RDKit Contributors (2023) RDKit: Open-source cheminformatics. Accessed 19 Sept 2025. http:\/\/www.rdkit.org"},{"key":"779_CR15","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1109\/TCBB.2021.3086702","volume":"19","author":"HI Kuru","year":"2022","unstructured":"Kuru HI, Tastan O, Cicek AE (2022) Matchmaker: a deep learning framework for drug synergy prediction. IEEE ACM Trans Comput Biol Bioinform 19:2334\u20132344. https:\/\/doi.org\/10.1109\/TCBB.2021.3086702","journal-title":"IEEE ACM Trans Comput Biol Bioinform"},{"key":"779_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13321-023-00690-3","volume":"15","author":"M Xu","year":"2023","unstructured":"Xu M, Zhao X, Wang J et al (2023) DFFNDDS: prediction of synergistic drug combinations with dual feature fusion networks. J Cheminform 15:33. https:\/\/doi.org\/10.1186\/s13321-023-00690-3","journal-title":"J Cheminform"},{"key":"779_CR17","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccm.2011.09.001","volume":"32","author":"CS Dela Cruz","year":"2011","unstructured":"Dela Cruz CS, Tanoue LT, Matthay RA (2011) Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 32:605\u2013644. https:\/\/doi.org\/10.1016\/j.ccm.2011.09.001","journal-title":"Clin Chest Med"},{"key":"779_CR18","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard D, J\u00e4nne PA, Cheng Y et al (2023) Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med 389:1935\u20131948. https:\/\/doi.org\/10.1056\/NEJMoa2306434","journal-title":"N Engl J Med"},{"key":"779_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"779_CR20","unstructured":"The Netherlands Cancer Institute (2019) Phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA-1 or -2 mutated HER2 negative advanced breast cancer as first line treatment. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02418624. (Accessed 19 Sept 2025)"},{"key":"779_CR21","unstructured":"University of Maryland, Baltimore (2022) A phase II study of letrozole in combination with lapatinib followed by an addition of everolimus in postmenopausal women with advanced endocrine resistant breast cancer. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01499160. (Accessed 19 Sept 2025)"},{"key":"779_CR22","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375:1925\u20131936. https:\/\/doi.org\/10.1056\/NEJMoa1607303","journal-title":"N Engl J Med"},{"key":"779_CR23","doi-asserted-by":"publisher","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","volume":"27","author":"S Johnston","year":"2009","unstructured":"Johnston S, Pippen J Jr, Pivot X et al (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538\u20135546. https:\/\/doi.org\/10.1200\/JCO.2009.23.3734","journal-title":"J Clin Oncol"},{"key":"779_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2147\/BCTT.S12150","volume":"3","author":"P Merriam","year":"2011","unstructured":"Merriam P, Sikov WM (2011) Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer. Breast Cancer 3:139\u2013150. https:\/\/doi.org\/10.2147\/BCTT.S12150","journal-title":"Breast Cancer"},{"key":"779_CR25","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1200\/JCO.2014.58.3401","volume":"33","author":"BM Slomovitz","year":"2015","unstructured":"Slomovitz BM, Jiang Y, Yates MS et al (2015) Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol 33:930\u2013936. https:\/\/doi.org\/10.1200\/JCO.2014.58.3401","journal-title":"J Clin Oncol"},{"key":"779_CR26","doi-asserted-by":"publisher","DOI":"10.4081\/oncol.2017.323","volume":"11","author":"AB Castrellon","year":"2017","unstructured":"Castrellon AB (2017) Novel strategies to improve the endocrine therapy of breast cancer. Oncol Rev 11:323. https:\/\/doi.org\/10.4081\/oncol.2017.323","journal-title":"Oncol Rev"}],"container-title":["Interdisciplinary Sciences: Computational Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12539-025-00779-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12539-025-00779-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12539-025-00779-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T16:03:28Z","timestamp":1786550608000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12539-025-00779-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["779"],"URL":"https:\/\/doi.org\/10.1007\/s12539-025-00779-3","relation":{},"ISSN":["1913-2751","1867-1462"],"issn-type":[{"value":"1913-2751","type":"print"},{"value":"1867-1462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"11 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors are required to disclose financial or non-financial interests that are directly or indirectly related to the work submitted for publication.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}